Cadila secures US FDA approval for epilepsy drug
Essential IR Insights Newsletter Fall - 2023
A Corporation Clearly Pinpoints Activist Investor Activity
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Cadila Healthcare Ltd., under the aegis of Zydus Cadila, secured the U.S. Food and Drug Administration approval for Felbamate tablets.
The drug is used for the treatment of seizures in people with epilepsy.
